Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael W Deininger

Showing results (21-30 of 160) with videos related to

Pageof 16
Sort By:
Oncotarget|March 2, 2013
New concepts for CML clonalityJamshid S Khorashad, Michael W Deininger, Thomas O'Hare
Hematology/Oncology Clinics of North America|July 5, 2017
Mechanisms of Resistance to ABL Kinase Inhibition in Chronic Myeloid Leukemia and the Development of Next Generation ABL Kinase InhibitorsAmi B Patel, Thomas O'Hare, Michael W Deininger
Expert Opinion on Investigational Drugs|May 22, 2008
New Bcr-Abl inhibitors in chronic myeloid leukemia: keeping resistance in checkThomas O'Hare, Christopher A Eide, Michael W Deininger
Journal of the National Cancer Institute|June 26, 2008
Persistent LYN signaling in imatinib-resistant, BCR-ABL-independent chronic myelogenous leukemiaThomas O'Hare, Christopher A Eide, Michael W Deininger
Clinical Lymphoma & Myeloma|March 27, 2007
Bcr-Abl kinase domain mutations and the unsettled problem of Bcr-AblT315I: looking into the future of controlling drug resistance in chronic myeloid leukemiaThomas O'Hare, Christopher A Eide, Michael W Deininger
Cancer Journal (Sudbury, Mass.)|December 14, 2011
Development of an effective therapy for chronic myelogenous leukemiaDavid W Woessner, Carol S Lim, Michael W Deininger
Blood|October 3, 2009
Same mutation, different alleleKarl J Aichberger, Angela G Fleischman, Michael W Deininger
Haematologica|February 12, 2026
Intrinsic cellular resistance to BCR::ABL1 inhibitorsNataly Cruz-Rodriguez, Yulieth Torres-Llanos, Michael W Deininger
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 3, 2016
New Strategies in Myeloproliferative Neoplasms: The Evolving Genetic and Therapeutic LandscapeAmi B Patel, Nadeem A Vellore, Michael W Deininger
Expert Review of Hematology|May 18, 2017
Treating the chronic-phase chronic myeloid leukemia patient: which TKI, when to switch and when to stop?Ami B Patel, Brandon W Wilds, Michael W Deininger
Pageof 16

Showing results (21-30 of 160) with videos related to

Sort By:
Pageof 16
Oncotarget|March 2, 2013
New concepts for CML clonalityJamshid S Khorashad, Michael W Deininger, Thomas O'Hare
Hematology/Oncology Clinics of North America|July 5, 2017
Mechanisms of Resistance to ABL Kinase Inhibition in Chronic Myeloid Leukemia and the Development of Next Generation ABL Kinase InhibitorsAmi B Patel, Thomas O'Hare, Michael W Deininger
Expert Opinion on Investigational Drugs|May 22, 2008
New Bcr-Abl inhibitors in chronic myeloid leukemia: keeping resistance in checkThomas O'Hare, Christopher A Eide, Michael W Deininger
Journal of the National Cancer Institute|June 26, 2008
Persistent LYN signaling in imatinib-resistant, BCR-ABL-independent chronic myelogenous leukemiaThomas O'Hare, Christopher A Eide, Michael W Deininger
Clinical Lymphoma & Myeloma|March 27, 2007
Bcr-Abl kinase domain mutations and the unsettled problem of Bcr-AblT315I: looking into the future of controlling drug resistance in chronic myeloid leukemiaThomas O'Hare, Christopher A Eide, Michael W Deininger
Cancer Journal (Sudbury, Mass.)|December 14, 2011
Development of an effective therapy for chronic myelogenous leukemiaDavid W Woessner, Carol S Lim, Michael W Deininger
Blood|October 3, 2009
Same mutation, different alleleKarl J Aichberger, Angela G Fleischman, Michael W Deininger
Haematologica|February 12, 2026
Intrinsic cellular resistance to BCR::ABL1 inhibitorsNataly Cruz-Rodriguez, Yulieth Torres-Llanos, Michael W Deininger
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 3, 2016
New Strategies in Myeloproliferative Neoplasms: The Evolving Genetic and Therapeutic LandscapeAmi B Patel, Nadeem A Vellore, Michael W Deininger
Expert Review of Hematology|May 18, 2017
Treating the chronic-phase chronic myeloid leukemia patient: which TKI, when to switch and when to stop?Ami B Patel, Brandon W Wilds, Michael W Deininger
Pageof 16